Pharma’s Biggest Dealmakers Face More Than M&A Risks – Bloomberg
Bloomberg |
Pharma’s Biggest Dealmakers Face More Than M&A Risks
Bloomberg The age of gene therapies – medicines that work by altering human genes – is arriving, and with it, the potential for curing diseases with one-and-done treatments. But parts of the pharma world, including some of this year’s biggest dealmakers, are … |
Immuno-Oncology News |
1st Patient Treated in Phase 1 Trial of FS118, Potential Immunotherapy for Advanced Cancers
Immuno-Oncology News A Phase 1 trial testing FS118 – F-star’s antibody designed to target two immune checkpoint proteins – in solid and advanced cancers has dosed a first patient, the company announced. The U.S.-based study (NCT03440437) is expected to enroll 51 patients … |
Immuno-Oncology News |
1st Patient Treated in Phase 1 Trial of FS118, Potential Immunotherapy for Advanced Cancers
Immuno-Oncology News A Phase 1 trial testing FS118 – F-star’s antibody designed to target two immune checkpoint proteins – in solid and advanced cancers has dosed a first patient, the company announced. The U.S.-based study (NCT03440437) is expected to enroll 51 patients … |